nous amphotericin B, and fluconazole, which is available through a donation program, is often the only treatment option.
Evidence suggests that outcomes in patients who are treated with fluconazole therapy at a dosage of 200 or 400 mg per day (as used in earlier trials) are poor [3] [4] [5] . In Zambia, the median duration of survival for patients receiving fluconazole at a dosage of 200 mg per day was only 19 days [3] . The 10-week mortality associated with initial fluconazole monotherapy at 200 or 400 mg per day of ∼50% that was reported by Schaars et al. [4] in South Africa represents a minimum estimate, given the retrospective nature of the study and incomplete outpatient follow-up. Recent work from Cape Town, South Africa, has demonstrated that, when administered at 400 mg per day, fluconazole is essen-tially fungistatic over the first 2 weeks of treatment [5] . The resulting prolonged period with a high viable organism load may predispose patients to the development of fluconazole resistance. In a recent study [6] , such resistance was a significant problem when initial therapy was fluconazole administered at 400 mg per day.
In light of this data, and taking into account the safety and availability of fluconazole, some centers and countries have recently adopted 800 mg as the initial treatment dose [7, 8] .
In support of this, and accepting the caveats of comparing across trials and the small numbers of patients in the higherdose cohorts, there is some suggestion that time to sterilization of CSF decreases as the dosage of fluconazole is increased from 200 to 800 mg per day. Time to CSF sterilization was a median of 64 days in a study in which patients received 200-400 mg of fluconazole per day [9] , a mean of 41 days in a study in which patients received 400 mg per day [10] , and a median of 21 days and 33 days in 2 studies in which the patients received 800 mg per day [11, 12] . In addition, the recent trial reported by Pappas et al. [13] suggests the superiority of 800 mg of fluconazole per day over 400 mg of fluconazole per day in treating CM in Thailand (in both regimens, fluconazole was administered in combination with amphotericin B).
However, dosages 1800 mg per day have also been given to smaller numbers of patients with cryptococcal disease and other severe fungal infections, and no evidence of serious toxicity has been found in patients receiving up to 1600 mg per day [14, 15] ; in addition, there has been some suggestion of increased efficacy associated with higher dosage [15] . The plasma concentration-dosage relationship is known to be linear with fluconazole dosages up to 2 g per day [14] . Therefore, in southwest Uganda, where standard treatment before our study was 400 mg of fluconazole per day, we undertook a dose escalation cohort study to determine the effect of increasing the fluconazole dosage from 800 mg per day to 1200 mg per day on the rate of clearance of cryptococcal infection.
PATIENTS AND METHODS
Our study was conducted at Mbarara University Hospital, Mbarara, in southwestern Uganda. It was approved by the Research Ethics Committee of Mbarara University of Science and Technology, the Wandsworth Local Research Ethics Committee (covering St. Georges University of London; London, UK), and the Uganda National Council for Science and Technology.
HIV-infected patients aged у18 years who were hospitalized with a first episode of CM diagnosed by CSF India ink test were eligible for enrollment in the study. The diagnosis of CM was confirmed by a CSF culture positive for Cryptococcus neoformans. Patients were excluded if they had alanine transaminase (ALT) levels 15 times the upper limit of normal (1200 U/ L), were pregnant, had a previous serious reaction to fluconazole, had received fluconazole within the previous month, or were already receiving antiretroviral therapy (ART). Patients already receiving ART were excluded, because they have a much lower initial fungal burden than do other patients [5] , which might make assessment of fungal clearance over a 2-week period less precise in these individuals, and because of concern that receiving ART might affect clearance and, therefore, constitute a confounding factor. Written informed consent was obtained from each patient or from the next of kin for patients with altered mental status.
Interventions. For the first 2 weeks, 30 patients were treated with fluconazole (Diflucan; Pfizer) at a dosage of 800 mg per day, and 30 patients were treated with fluconazole at a dosage of 1200 mg per day. After 2 weeks, all patients received fluconazole at a dosage of 400 mg per day for 8 weeks and 200 mg per day thereafter. The dosage was adjusted for patients with significant renal impairment, and the consolidation and maintenance dosage (after the first 2 weeks) was increased by 50% for patients receiving concomitant rifampicin.
Follow-up lumbar punctures were performed on days 3, 7, and 14. Patients with CSF opening pressure 135 cm water and/ or headache or other symptoms attributable to increased pressure underwent additional lumbar punctures [16] . After hospital discharge, participants were counselled and initiated ART (nevirapine or efavirenz, plus stavudine and lamivudine, administered in accordance with Ugandan Ministry of Health guidelines) 1-8 weeks after the start of antifungal therapy (median time to ART initiation, 5 weeks) and were followed up for 6 months from the date of enrollment.
Evaluation and outcomes. At baseline, all participants had complete blood cell counts, CD4 + cell counts, and electrolyte, urea, creatinine, and ALT measurements. The complete blood cell counts and electrolyte, urea, creatinine, and ALT measurements were repeated on days 7 and 14. The final serum ALT level was the last value obtained during the 2-week treatment period. Peak values were the highest values at any point during the treatment course. Percentage change of a value was calculated using the following formula: (final value Ϫ baseline value/baseline . value) ϫ 100% CSF samples were analyzed for cell count and differential cell count, protein level, and glucose level, and India ink tests and quantitative fungal cultures were performed, as described elsewhere [17] . In brief, as soon as possible after lumbar puncture, CSF samples were serially diluted 10-fold, and 100 mL of each dilution was spotted onto each half of a Sabouraud dextrose agar plate. Counts were taken from the plate with the lowest dilution that had at least 30 colonies. Cryptococcal clearance rates were calculated using a summary statistic for each patient, which was defined as the decrease in log colony-forming units (CFU) per mL of CSF per day, by use of the slope of the linear regression of log CFU against time for each patient [17] . The primary outcome measure was the mean rate of decrease in CSF cryptococcal CFU, or early fungicidal activity (EFA), for each of the 2 cohorts. Secondary outcome measures were change in ALT level and mortality at 2 and 10 weeks.
Statistics. Linear regression was used to compare mean rates of decrease in CSF cryptococcal CFU (i.e., EFA) by treatment cohort, adjusting for other variables if indicated, giving summary differences with 95% CIs and significance levels [17] . A P value of !.05 was considered to be statistically significant. Baseline characteristics and outcomes in the cohorts were compared by the x 2 test for categorical variables and by the MannWhitney U test or Student's t test for continuous variables. Analyses were performed using Stata software, version 8 (Stata).
RESULTS

From August 2005 through May 2007, 60 patients with India
ink test results and CSF cultures positive for C. neoformans were enrolled in the study. The first 30 patients received fluconazole at a dosage of 800 mg per day (group 1), and the next 30 patients received fluconazole at a dosage of 1200 mg per day (group 2). Forty-one patients with a positive India ink test result were screened for group 1. Of these, 8 patients were excluded because they had already initiated ART, 2 declined consent, and 1 had received fluconazole within the past month. Fifty-five patients with a positive India ink test result were screened for group 2. Of these, 16 patients were excluded because they had already initiated ART, 4 declined consent, 4 were unable to provide consent and had no next of kin with whom to discuss consent, and 1 had received fluconazole within the past month.
Baseline clinical and laboratory characteristics and clinical outcomes are shown in table 1. At the time of presentation with CM, the overall median CD4 + cell count was 6 12 ϫ 10 cells/L, and the median baseline fungal burden was 622,500 CFU/mL. Twenty-eight patients (47%) had altered mental status (Glasgow coma scale, !15) at presentation. There were significantly more patients with altered mental status at presentation in group 2 than in group 1.
EFA. All of the enrolled patients were analyzed for rate of clearance of infection, with the exception of 1 patient who died before the first follow-up lumbar puncture and whose infection clearance could not be assessed. The rate of clearance of infection during the first 2 weeks of therapy was more rapid in group 2 than in group 1. EFA (‫ע‬SD) was log Ϫ0.07 ‫ע‬ 0.17 CFU/mL per day for group 1 and CFU/mL per Ϫ0.18 ‫ע‬ 0.11 day for group 2 (figure 1).
The difference in rate of clearance was 0.11 log CFU/mL per day (95% CI, 0.03-0.18 log CFU/mL per day;
). In P p .006 contrast with previous datasets [17, 18] , baseline CSF CFU count was not significantly associated with rate of clearance ( ; ); there was no statistically significant assor p 0.07 P p .6 ciation between rate of clearance and altered mental status, age, sex, or CSF WBC count. The only other factor that was associated with rate of clearance was CD4 + cell count; patients 1 ϫ 10 mL. The decrease in log CFU/mL per day was calculated for each patient with use of the slope of the linear regression of log CFU against time. For each cohort, early fungicidal activity (EFA) is shown as the mean rate of decrease in log CFU counts. EFA was statistically significantly greater for patients receiving 1200 mg of fluconazole per day (group 2; n p ) than it was for those receiving 800 mg of fluconazole per day (group 29 1; ; ). n p 30 P p .007 with higher CD4 + cell counts had more-rapid clearance (increase in rate of clearance, 0.07 log CFU/mL per day [95% CI, 0.04-0.10 log CFU/mL per day] for each increment in CD4 + cell count quartile;
). In a linear regression model that P ! .001 included fluconazole dosage and CD4 + cell count, both of these factors remained independently associated with rate of clearance, and the estimates of effect were little changed. EFA was significantly greater for patients receiving fluconazole at a dosage of 1200 mg per day, compared with those receiving fluconazole at 800 mg per day (difference in EFA, 0.10 log CFU/ mL per day; 95% CI, 0.03-0.16 log CFU/mL per day; P p ), and was significantly greater for patients with higher .007 CD4 + cell counts (increase in rate of clearance, 0.07 log CFU/ mL per day [95% CI, 0.04-0.10 log CFU/mL per day] for each increment in CD4 + cell count quartile; ). P ! .001 Safety. Fluconazole at both dosages appeared to be well tolerated. No patients discontinued fluconazole therapy because of suspected adverse reactions before completing 14 days of treatment. There was no statistically significant difference between the 2 dosage groups in the percentage change in ALT level during the first 2 weeks of therapy (median percentage change in ALT level [interquartile range], 16% [Ϫ8% to 68%] for group 1 vs. 15% [Ϫ23% to 36%] for group 2;
). P p .62 Similarly, baseline, peak, and final ALT levels did not differ significantly between the 2 dosage groups (table 1) . No patient developed clinical jaundice during the follow-up period.
Mortality. At 6 months after initiation of treatment, 3 patients in group 2 had been lost to follow-up, all within the first 2 weeks of treatment. Overall mortality was 30% at 2 weeks (17 of 57 patients died) and 54% at 10 weeks (31 of 57 patients died); there was no statistically significant difference between the 2 groups at either time point (table 1) . At 6 months, 9 (30%) of 30 patients in group 1 and 13 (43%) of 30 patients in group 2 were known to be alive and receiving ART.
DISCUSSION
This study demonstrated a statistically significant increase in EFA when fluconazole dosage was increased from 800 to 1200 mg per day. The difference was not affected by adjustment for other factors that affected rate of clearance in this or other datasets, making it unlikely that the difference was attributable to imbalances between the groups that may have been caused by the cohort nature of the study. When added to data derived from several patients who received treatment in Cape Town, South Africa, with fluconazole at a dosage of 400 mg per day (EFA, Ϫ0.02 log CFU/mL per day) [5] , these results suggest that the EFA of fluconazole increases approximately linearly with increasing dosage over this dosage range (figure 2). Such an increase would be consistent with the known pharmacokinetics and proposed area under the curve/MIC-dependent pharmacodynamics of fluconazole [19] .
No evidence for an increase in toxicity at the higher dosage was observed, although the number of patients studied was small. However, fluconazole at a dosage of 1200 mg per day has been used to treat a variety of serious or refractory fungal infections without evidence for increased serious toxicity [14, 15, 20, 21] . Indeed, in coccidioidal meningitis, some experts routinely administer fluconazole at this dosage [22] . Our study was not powered to determine differences in mortality. Nevertheless, there were more known survivors at 6 months in group 2 than in group 1, despite the fact that group 2 included a higher proportion of patients with altered mental status at presentation, which is the most important predictor of poor prognosis in cryptococcal meningitis.
It should be emphasized that this was a minimally selected and severely ill population; the overall proportion of patients with a reduced level of consciousness at presentation and the median baseline organism load were both markedly higher than in previous studies from Thailand and South Africa [5, 17, 18] . This may reflect late presentation, as emphasized by a previous study from the national referral hospital in Kampala, Uganda, that reported a 2-week mortality of 42% in a series of unselected patients with cryptococcal meningitis, despite the availability of amphotericin B therapy [23] . Efforts are needed to promote awareness of the clinical significance of headache in patients with possible late-stage HIV infection, and studies are needed to test strategies to facilitate rapid referral, diagnosis, and initiation of therapy for patients with cryptococcal disease [24] or to screen for early, subclinical disease. Of note, the same group recently reported outcomes for a cohort of patients (excluding comatose patients) treated with amphotericin B during 2006; these outcomes were similar to those of group 2 in our study, with 41% survival 6 months after ART initiation [25] , compared with 43% survival at 6 months in group 2.
Quantitative fungal cultures of CSF samples were sometimes helpful in managing the cases of patients who presented to the hospital for a second time soon after their initial hospital admission, at a time when CSF cultures would still be expected to have positive results for most patients. An additional decrease in CFU count, compared with the CFU count for the most recent CSF sample obtained before discharge from the hospital, supported a diagnosis of immune reconstitution in those patients who had started ART, whereas an increase in CFU count despite reported adherence to consolidation or maintenance fluconazole therapy was suggestive of the possibility of developing fluconazole resistance. Maintaining high-dose fluconazole therapy after the first 2 weeks, at least until ART is started, might reduce the risk of developing resistance and improve outcome. Questions remain regarding the safety of high-dose fluconazole when administered in combination with nonnucleoside reverse-transcriptase inhibitors (in particular, nevirapine) [26, 27] .
Additional studies are required, building on the work of Larsen et al. [15] , to determine a full dose response for fluconazole. However, it seems to be likely, based on these results, that even at optimal dosing, treatment with fluconazole will clear cryptococcal infection less rapidly than will amphotericin B-based regimens, which have been associated with rates of clearance of 0.31-0.56 log CFU/mL per day in earlier studies [5, 17, 18] . Thus, 2 additional strategies need testing urgently in settings in which 2 weeks of amphotericin B-based treatment is not yet feasible: addition of flucytosine to optimized fluconazole in an oral regimen and addition of short course (5-7-day) amphotericin B therapy to optimized fluconazole therapy. An optimized oral regimen also needs to be tested against amphotericin B-based therapy. In the meantime, at African health care centers where fluconazole is currently used, these data would support the use of 1200 mg per day as the initial dosage, with continued vigilance for the possibility of rare drug-related adverse events.
